Press Releases March 30, 2026

AirSculpt Technologies Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call

AirSculpt Technologies to release Q4 and FY2025 earnings with a follow-up conference call

By Leila Farooq AIRS
AirSculpt Technologies Announces Fourth Quarter and Fiscal Year 2025 Earnings Release Date and Conference Call
AIRS

AirSculpt Technologies, leader in premium body contouring procedures, announced its forthcoming Q4 and full fiscal year 2025 earnings release scheduled before market open on April 2, 2026, followed by a conference call and webcast for investors.

Key Points

  • Earnings for Q4 and full fiscal year 2025 will be reported on April 2, 2026, before market open.
  • A conference call and live webcast will provide insights and Q&A opportunities for investors immediately after the earnings release.
  • AirSculpt offers minimally invasive body contouring treatments that emphasize comfort and precision, impacting the cosmetic and healthcare sectors.

MIAMI BEACH, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report fourth quarter and fiscal year 2025 financial results before market open on Thursday, April 2, 2026, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time.

The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13758597 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days.

About AirSculpt

AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Investor Contact:

Allison Malkin
Partner, ICR Inc.
[email protected]


Risks

  • Financial results may fall short of market expectations, impacting stock price negatively in the healthcare and consumer discretionary sectors.
  • Market reception of the earnings call could be muted if no significant operational updates or growth guidance is provided.
  • Any regulatory or operational challenges related to medical procedures could affect company performance and investor sentiment.

More from Press Releases

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders Apr 3, 2026 Midland States Bancorp, Inc. To Announce First Quarter 2026 Financial Results On Thursday, April 23 Apr 3, 2026 Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Apr 3, 2026 Multi-Sensor Data Labeling and AI Data Operations: What Enterprise AV Teams Apr 3, 2026 Wix Announces Final Results of Modified Dutch Auction Tender Offer Apr 3, 2026